Trial Profile
A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Intervention compared to standard treatment with narrow band UVB (STEPIn study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Betamethasone; Calcipotriol
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms STEPIn
- Sponsors Novartis; Novartis Pharmaceuticals
- 18 Sep 2023 Status changed from active, no longer recruiting to completed.
- 07 Sep 2023 This trial has been discontinued in Spain(End Date: 16 Jun 2023), according to the European Clinical Trials Database record.
- 13 Jul 2023 This trial has been discontinued in Bulgaria (Date of the global end of the trial: 16-Jun-2023), according to the European Clinical Trials Database record.